Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc to Discuss Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update Call Transcript

May 28, 2019 / 12:00PM GMT
Release Date Price: $86.44 (-0.88%)
Operator

Welcome to the BioMarin valrox Phase II/Phase III Update Call. (Operator Instructions) And today's call is being recorded.

It is now my pleasure to turn today's program over to Ms. Traci McCarty. Please go ahead.

Traci McCarty
BioMarin Pharmaceutical Inc. - VP of IR

Thank you, operator, and thank you all for joining us this morning to discuss the Phase II and Phase III data update with valoctocogene roxaparvovec or valrox for the treatment of severe hemophilia A. Today's press releases are available on the Investor page of our website and today's slide presentation will be posted at the end of this call. For viewing the slides being presented during the call now, you can access them via the webcast link on the press release.

On the call today from BioMarin management are J.J. Bienaimé, our Chairman and CEO; and Dr. Hank Fuchs, BioMarin's President Worldwide Research and Development; and joining during the Q&A portion of today's call is Dan Spiegelman, Executive Vice President and CFO; and Robert Baffi, Executive Vice President,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot